Jane C. Davies

发表

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung

D. Porteous, R. Scheule, J. Davies, 2013, Gene Therapy.

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

D. Porteous, J. Davies, M. Hasegawa, 2012, American journal of respiratory and critical care medicine.

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis

D. Porteous, G. Murray, Seng H. Cheng, 2013, Thorax.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016, Thorax.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

Steve Cunningham, Joseph Jacob, Sarah Sheard, 2015 .

Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.

D. Geddes, M. Evans, W. Colledge, 2001, The European respiratory journal.

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis

A. Nicholson, D. Hansell, A. Maclean, 2016 .

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

M. Hasegawa, S. Hyde, R. Farley, 2012, American journal of respiratory and critical care medicine.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

A. Nicholson, D. Hansell, A. Maclean, 2015, The Lancet. Respiratory medicine.

T4 Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis

R. Scheule, S. Hyde, D. Gill, 2011, Thorax.